Literature DB >> 14694056

Experience with immunomodulatory treatments in Rasmussen's encephalitis.

T Granata1, L Fusco, G Gobbi, E Freri, F Ragona, G Broggi, R Mantegazza, L Giordano, F Villani, G Capovilla, F Vigevano, B Dalla Bernardina, R Spreafico, C Antozzi.   

Abstract

The authors investigated immunomodulatory treatments in 15 patients with Rasmussen encephalitis (RE) (14 with childhood and one with adolescent onset RE). Positive time-limited responses were obtained in 11 patients using variable combinations of corticosteroids, apheresis, and high-dose IV immunoglobulins. Although surgical exclusion of the affected hemisphere is the only treatment that halts disease progression, immunomodulation can be considered when early surgery is not feasible, in late-onset patients with slower disease progression, and in the few cases of bilateral disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14694056     DOI: 10.1212/01.wnl.0000099074.04539.e0

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  30 in total

Review 1.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

2.  Rasmussen's encephalitis, should absence of seizures influence or delay treatment?

Authors:  K M Gorman; M Farrell; C Madigan; M D King; A Shahwan
Journal:  Childs Nerv Syst       Date:  2015-09-26       Impact factor: 1.475

Review 3.  IVIG therapy in neurological disorders of childhood.

Authors:  Juan J Archelos; Franz Fazekas
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

4.  Humanized mouse model of Rasmussen's encephalitis supports the immune-mediated hypothesis.

Authors:  Hania Kebir; Lionel Carmant; François Fontaine; Kathie Béland; Ciprian M Bosoi; Nathalie T Sanon; Jorge I Alvarez; Sébastien Desgent; Camille L Pittet; David Hébert; Marie-Josée Langlois; Rose-Marie Rébillard; Dang K Nguyen; Cécile Cieuta-Walti; Gregory L Holmes; Howard P Goodkin; John R Mytinger; Mary B Connolly; Alexandre Prat; Elie Haddad
Journal:  J Clin Invest       Date:  2018-04-09       Impact factor: 14.808

Review 5.  Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications.

Authors:  Nicolas Collongues; Laure Michel; Jérôme de Seze
Journal:  Curr Treat Options Neurol       Date:  2017-05       Impact factor: 3.598

Review 6.  Rasmussen encephalitis with dual pathology in a patient without seizures: case report and literature review.

Authors:  Vijay M Ravindra; Marcus D Mazur; Carrie A Mohila; Matthew T Sweney; Aimee Hersh; Robert J Bollo
Journal:  Childs Nerv Syst       Date:  2015-06-02       Impact factor: 1.475

7.  Immunotherapy in Rasmussen's encephalitis: when should it be taken into account?

Authors:  L Papetti; A Spalice; F Nicita; F Ursitti; P Iannetti
Journal:  Neurol Sci       Date:  2012-09-25       Impact factor: 3.307

Review 8.  Mechanisms of epileptogenesis in pediatric epileptic syndromes: Rasmussen encephalitis, infantile spasms, and febrile infection-related epilepsy syndrome (FIRES).

Authors:  Carlos A Pardo; Rima Nabbout; Aristea S Galanopoulou
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

Review 9.  Treatment of Generalized Convulsive Status Epilepticus in Pediatric Patients.

Authors:  Elizabeth L Alford; James W Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jul-Aug

Review 10.  Finding on brain MRI mimicking focal cortical dysplasia in early Rasmussen's encephalitis: a case report and review.

Authors:  Kuo-Liang Chiang; Tai-Tong Wong; Shan-Young Kwan; Ting-Rong Hsu; Chung-Hao Wang; Kai-Ping Chang
Journal:  Childs Nerv Syst       Date:  2009-06-11       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.